- Report
- July 2024
- 175 Pages
Global
From €4793EUR$5,000USD£4,005GBP
- Report
- October 2024
- 197 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- March 2025
- 183 Pages
Global
From €3399EUR$3,545USD£2,840GBP
€3776EUR$3,939USD£3,155GBP
- Report
- December 2024
- 120 Pages
Global
From €5704EUR$5,950USD£4,766GBP
- Report
- November 2024
- 110 Pages
Global
From €5704EUR$5,950USD£4,766GBP
- Report
- February 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- March 2025
- 144 Pages
Global
From €2875EUR$2,999USD£2,402GBP
- Report
- January 2025
- 176 Pages
Global
From €7621EUR$7,950USD£6,368GBP
- Drug Pipelines
- August 2024
- 180 Pages
Global
From €2397EUR$2,500USD£2,003GBP
- Report
- July 2024
- 150 Pages
Global
From €3595EUR$3,750USD£3,004GBP
- Report
- August 2024
- 150 Pages
Global
From €2674EUR$2,789USD£2,234GBP
- Report
- November 2022
- 230 Pages
Global
From €3595EUR$3,750USD£3,004GBP
- Report
- February 2024
- 250 Pages
Global
From €4793EUR$5,000USD£4,005GBP
- Report
- April 2021
China
From €2493EUR$2,600USD£2,083GBP
- Report
- January 2024
- 143 Pages
Global
From €4074EUR$4,250USD£3,404GBP
- Report
- June 2023
- 113 Pages
Global
From €4266EUR$4,450USD£3,565GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1198EUR$1,250USD£1,001GBP
- Report
- April 2023
- 114 Pages
Global
From €4554EUR$4,750USD£3,805GBP
- Report
- January 2022
- 105 Pages
Global
From €4554EUR$4,750USD£3,805GBP
- Report
- August 2024
- 80 Pages
Japan
From €3355EUR$3,500USD£2,804GBP

Tacrolimus is an immunosuppressant drug used to treat immune disorders such as rheumatoid arthritis, psoriasis, and Crohn's disease. It works by inhibiting the production of certain proteins that are involved in the body's immune response. Tacrolimus is typically administered orally or intravenously, and is available in both generic and branded forms. It is also used to prevent organ rejection in transplant patients.
Tacrolimus is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other drugs. It is generally well tolerated, with few side effects. However, it can cause serious side effects, such as an increased risk of infection and an increased risk of developing certain types of cancer.
The tacrolimus market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, and Sanofi. Other companies include Mylan, Teva, and Sun Pharmaceuticals. Show Less Read more